To summarize findings from transgenic mouse models and those gained from treatment with α2C-subtype-selective ligands, Table 2 presents neurochemical and behavioral findings reported in transgenic mice and in various rodent models predicting pro-cognitive-like, antidepressant-like and antipsychotic-like effects as described in Sections “Behavioural Deficits Associated With MDD,” “Behavioural Deficits Associated With Schizophrenia,” and “Cognitive Deficits Associated With MDD and Schizophrenia”. The gene discussed is IGKV2D-29; the disease is Cognitive impairment.